Radiopharmaceutical Theranostics Market Scope
To treat or diagnose cancer, radioactive drugs can be administered orally, intravenously, or intramuscularly. These medications are administered in the presence of a specialist known as a radio pharmacist. When these radioactive drugs reach their target cell, they generate radiation, which kills the malignant cells. Radiopharmaceuticals for the treatment and diagnosis of thyroid, brain, bone, and lymphoma malignancies have previously been found. Radiopharmaceutical Therapy (RPT) is gaining popularity as a safe and effective way to treat a variety of cancers. Radiopharmaceuticals are utilized not just for treatment but also for diagnosis. Tracers are the medications that are utilized for diagnosis. When compared to radiation emitted by radiopharmaceuticals used for therapy, diagnostic radiopharmaceuticals emit less radiation. Radiopharmaceuticals are either single isotopes or kits including many isotopes.
The Radiopharmaceutical Theranostics market study is segmented by Type (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18, Lutetium (Lu) 177, Copper (Cu) 67 and Others), by Application (Oncology, Cardiology and Others) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Radiopharmaceutical Theranostics market throughout the predicted period.
Nihon Medi-Physics (China), ITM Isotopen Technologien München AG (Germany), Advanced Accelerator Applications (France), Telix Pharmaceuticals (Australia), GE Healthcare (United States), Theragnostics Ltd. (United States), NuView Life Sciences (United States), Jubilant Pharma Limited (United States), Lantheus Holdings, Inc. (United States), Curium Pharma (United Kingdom), Bayer AG (Germany) and Clarity Pharmaceuticals (Australia) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Radiopharmaceutical Theranostics market by Type, Application and Region.
On the basis of geography, the market of Radiopharmaceutical Theranostics has been segmented into South America (Brazil, Argentina, Chile, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, Thailand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Spain, Sweden, Belgium, Poland, Norway, Austria, Russia, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 23rd Aug 2021 - Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI in radioguided surgery (RGS), On 15th June 2020 - Nihon Medi-Physics Co., Ltd (NMP), a leading radiopharmaceutical company in Japan and Global Medical Solutions, Ltd., (GMS), a leading-edge manufacturer and distributor of radiopharmaceuticals, diagnostic imaging products, equipment, devices, and services, announced today that they have signed an agreement for a strategic partnership in nuclear medicine markets in Asia and Oceania. and On 17th Feb 2021 - Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, has announces a research collaboration with Essen University Hospital to examine Theragnostics’ investigational agent THG-008 for PET imaging in a range of cancers.
In Europe, radiopharmaceutical compounds are considered a special group of medicines. Therefore, their preparation and use are regulated by a number of EU directives, regulations and rules that have been adopted by member states. and In United States, The NRC regulates the medical use of radioactive materials including regulations concerning radiation exposure. These regulations are promulgated via the Code of Federal Regulations.
- The Increase in Application of Radioisotopes in the Healthcare Industry
- Technological Advancements in the Diagnostics Sector
- Radiopharmaceuticals are Generating Major Oncology Deals Globally
- Rise in Incidence and Prevalence of Target Conditions
- Rise in Initiatives to Reduce the Demand-Supply Gap
- Rising Use of Radiopharmaceuticals for the Diagnosis and Treatment of Chronic Disease
- Short Half-Life of Radiopharmaceuticals and High Equipment Prices
Key Target AudienceHealthcare Industry, Regulatory Bodies, Radiopharmaceutical Providers, Government Bodies and Others